WHO Digital Documentation of COVID-19 Certificates (DDCC)
1.0.0 - CI Build
WHO Digital Documentation of COVID-19 Certificates (DDCC)
1.0.0 - CI Build
This page is part of the WHO Digital Documentation of COVID-19 Certificates (DDCC) (v1.0.0: releases Draft) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
| Official URL: http://smart.who.int/ddcc/ValueSet/VaccineCovid19CvxValueSet | Version: 1.0.0 | |||
| Draft as of 2024-10-15 | Computable Name: VaccineCovid19CvxValueSet | |||
This is a one-time snapshot of the allowed CVX codes for vaccines, retrieved in February 2023. Contents may need to be updated and readers should consult the credential documentation, found here http://hl7.org/fhir/uv/shc-vaccination/2021Sep/ValueSet-vaccine-cvx.html. More information on the CVX value set can be found here, https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
Generated Narrative: ValueSet VaccineCovid19CvxValueSet
http://hl7.org/fhir/sid/cvx| Code | Display |
| 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose |
| 208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose |
| 210 | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL |
| 211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL |
| 212 | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL |
| 213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED |
| 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose |
| 218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose |
| 219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose |
| 221 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose |
| 225 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL |
| 226 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL |
| 227 | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose |
| 228 | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose |
| 229 | COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose |
| 230 | COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL |
| 300 | COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose |
| 301 | COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose |
| 302 | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose |
| 500 | COVID-19 Non-US Vaccine, Product Unknown |
| 501 | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) |
| 502 | COVID-19 IV Non-US Vaccine (COVAXIN) |
| 503 | COVID-19 LAV Non-US Vaccine (COVIVAC) |
| 504 | COVID-19 VVnr Non-US Vaccine (Sputnik Light) |
| 505 | COVID-19 VVnr Non-US Vaccine (Sputnik V) |
| 506 | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology) |
| 507 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences) |
| 508 | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) |
| 509 | COVID-19 PS Non-US Vaccine (EpiVacCorona) |
| 510 | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) |
| 511 | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) |
| 512 | SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) |
| 513 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) |
| 514 | SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) |
| 515 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) |
| 516 | COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) |
| 517 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) |
| 518 | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) |
| 519 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna |
| 520 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech |
Generated Narrative: ValueSet
Expansion based on codesystem CVX codes used in this IG v1.0.0 (CodeSystem)
This value set contains 40 concepts
| Code | System | Display |
| 207 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose |
| 208 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose |
| 210 | http://hl7.org/fhir/sid/cvx | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL |
| 211 | http://hl7.org/fhir/sid/cvx | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL |
| 212 | http://hl7.org/fhir/sid/cvx | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL |
| 213 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED |
| 217 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose |
| 218 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose |
| 219 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose |
| 221 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose |
| 225 | http://hl7.org/fhir/sid/cvx | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL |
| 226 | http://hl7.org/fhir/sid/cvx | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL |
| 227 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose |
| 228 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose |
| 229 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose |
| 230 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL |
| 300 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose |
| 301 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose |
| 302 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose |
| 500 | http://hl7.org/fhir/sid/cvx | COVID-19 Non-US Vaccine, Product Unknown |
| 501 | http://hl7.org/fhir/sid/cvx | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) |
| 502 | http://hl7.org/fhir/sid/cvx | COVID-19 IV Non-US Vaccine (COVAXIN) |
| 503 | http://hl7.org/fhir/sid/cvx | COVID-19 LAV Non-US Vaccine (COVIVAC) |
| 504 | http://hl7.org/fhir/sid/cvx | COVID-19 VVnr Non-US Vaccine (Sputnik Light) |
| 505 | http://hl7.org/fhir/sid/cvx | COVID-19 VVnr Non-US Vaccine (Sputnik V) |
| 506 | http://hl7.org/fhir/sid/cvx | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology) |
| 507 | http://hl7.org/fhir/sid/cvx | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences) |
| 508 | http://hl7.org/fhir/sid/cvx | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) |
| 509 | http://hl7.org/fhir/sid/cvx | COVID-19 PS Non-US Vaccine (EpiVacCorona) |
| 510 | http://hl7.org/fhir/sid/cvx | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) |
| 511 | http://hl7.org/fhir/sid/cvx | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) |
| 512 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) |
| 513 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) |
| 514 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) |
| 515 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) |
| 516 | http://hl7.org/fhir/sid/cvx | COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) |
| 517 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) |
| 518 | http://hl7.org/fhir/sid/cvx | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) |
| 519 | http://hl7.org/fhir/sid/cvx | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna |
| 520 | http://hl7.org/fhir/sid/cvx | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |